Dossier assessment
Linagliptin - Re-assessment of benefit according to § 35a, Para. 5b, Social Code Book V (dossier assessment)
Report documents
-
Extract of dossier assessment
Linagliptin - Re-assessment of benefit according to § 35a, Para. 5b, Social Code Book V (dossier assessment)
-
Dossier assessment
Linagliptin - Re-assessment of benefit according to § 35a, Para. 5b, Social Code Book V (dossier assessment)
Press releases
Linagliptin: Once again, no proof of added benefit
Additional information
IQWiG health information
Federal Joint Committee (G-BA)
2012-02-21 A G-BA decision was published.
Project details
- Project no.
- A12-11
- Commission
- Commission awarded on 03.09.2012 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Digestion, metabolism and hormones
- Note
-
According to § 35a (5b) Social Code Book V, concerning decisions published up to 31 December, a pharmaceutical company may apply for a renewed benefit assessment at any time if the added benefit is considered to be "not proven" because the necessary evidence was not completely presented by the company. After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Linagliptin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed